Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.
AGC Biologics has completed the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at Heidelberg, Germany.
A biomanufacturing firm Wheeler Bio has launched a drug substance current good manufacturing practices (CGMP) facility in Oklahoma City, US.
Kincell Bio, a cell therapy contract development and manufacturing organisation (CDMO) spun out of Inceptor Bio, has launched with $36m investment with an aim to help early-stage innovators develop and manufacture cell therapies.
Contract development and manufacturing organisation (CDMO) Biovian has announced plans to make an investment worth more than $55m (€50m) to expand its manufacturing facility at Turku in Finland.
Samsung Biologics has announced a strategic collaboration with Pfizer for the long-term commercial manufacturing of the latter’s multi-product biosimilars portfolio.
Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) have announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia (difelikefalin) to treat chronic kidney disease (CKD)-associated pruritus.
Melinta Therapeutics and Xediton Pharmaceuticals have entered an exclusive commercialisation and licensing agreement for four novel anti-infective products.
The Food and Drug Administration (FDA) has successfully inspected Nexus Pharmaceuticals’ pharmaceutical manufacturing facility located in Pleasant Prairie, Wisconsin, US.
The US Food and Drug Administration (FDA) has granted approval for Ajinomoto Bio-Pharma Services’ high potency vial line to manufacture a commercial product.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.